)
Skye Bioscience (SKYE) investor relations material
Skye Bioscience Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Voting matters and shareholder proposals
Election of six directors: Paul Grayson, Deborah Charych, Punit Dhillon, Annalisa Jenkins, Karen Smith, and Andrew J. Schwab, with board recommending a vote for all nominees.
Ratification of CBIZ CPAS P.C. as independent registered public accounting firm for the year ending December 31, 2026.
Approval of an amendment to increase authorized common stock from 100,000,000 to 300,000,000 shares.
Advisory vote on executive compensation as disclosed in the proxy statement.
Other business may be addressed as appropriate at the meeting or any adjournment.
Board of directors and corporate governance
Six director nominees are presented for election at the annual meeting.
Executive compensation and say-on-pay
Advisory vote scheduled on the compensation of named executive officers, following SEC disclosure rules.
- Shareholders will vote on director elections, auditor ratification, share increase, and executive pay.SKYE
Proxy filing16 Apr 2026 - Nimacimab plus semaglutide delivers durable, significant weight loss with strong safety and commercial potential.SKYE
Corporate presentation7 Apr 2026 - Shareholders to vote on board elections, auditor ratification, share increase, and executive pay.SKYE
Proxy filing6 Apr 2026 - Shareholders to vote on board elections, auditor, share increase, and executive pay amid clinical progress.SKYE
Proxy filing6 Apr 2026 - Nimacimab plus semaglutide delivers durable, additive weight loss with strong safety and R&D momentum.SKYE
Q4 202510 Mar 2026 - Nimacimab plus semaglutide delivers superior, durable weight loss with strong safety and financial backing.SKYE
Corporate presentation10 Mar 2026 - Phase 2 obesity trial for nimacimab advances, net loss narrows, and cash position remains strong.SKYE
Q3 202415 Jan 2026 - Phase II trial of nimacimab targets safe, effective obesity treatment with 2025 milestones ahead.SKYE
Guggenheim Global Healthcare Conference15 Jan 2026 - Phase 2 data for a novel CB1 antibody in obesity, targeting 8% weight loss, expected Q2 2025.SKYE
UBS Global Healthcare Conference14 Jan 2026
Next Skye Bioscience earnings date
Next Skye Bioscience earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage